Monistat

Monistat is a United States consumer-health brand best known for over-the-counter treatments for vaginal yeast infections. Its principal active ingredient is miconazole nitrate, an azole antifungal that works by disrupting the fungal cell membrane. The brand is sold in several treatment durations and dosage forms, allowing consumers to choose between shorter and longer courses according to product labeling and personal preference. The core Monistat portfolio has historically centered on intravaginal products, including one-, three-, and seven-day treatment regimens. These products generally combine an applicator-delivered ovule, suppository, or cream with packaging and instructions intended for self-treatment. The brand has also marketed external-use products for temporary relief of itching and irritation associated with a yeast infection. Such products are adjuncts for external symptoms rather than substitutes for the antifungal treatment itself. Monistat occupies the self-care segment of the women's health and vaginal-health market. Its principal competitive set includes other miconazole products, clotrimazole products, and prescription or over-the-counter treatments based on other antifungal ingredients. The brand's consumer proposition is built around recognizable name recognition, pharmacy availability, multiple course lengths, and the convenience of nonprescription treatment for people who have previously experienced medically diagnosed vaginal yeast infections. The brand's ownership has changed over time. It was formerly associated with Insight Pharmaceuticals, a privately held consumer-health company whose portfolio included several over-the-counter brands. Prestige Consumer Healthcare acquired Insight Pharmaceuticals in 2016, bringing Monistat into Prestige's North American consumer-health portfolio. Prestige describes Monistat as one of its women's health brands and markets it alongside other self-care products. Because symptoms associated with yeast infections can overlap with bacterial vaginosis, sexually transmitted infections, allergic reactions, and other conditions, Monistat labeling advises consumers to seek medical advice in circumstances such as a first suspected infection, recurrent infections, pregnancy, unusual symptoms, or failure to improve. Product labeling also warns that local burning, itching, or irritation can occur and that treatment should be used according to the directions for the specific formulation. The brand remains active in the U.S. over-the-counter market, with its products distributed through pharmacies, mass retailers, grocery stores, and e-commerce channels.

Monistat developed as a consumer healthcare brand for the treatment of vaginal candidiasis, commonly called a vaginal yeast infection. Its products use miconazole nitrate, an imidazole-class antifungal that inhibits the growth of susceptible fungi. The brand became associated with the expansion of self-care options for vaginal infections because its products could be purchased without a prescription in the United States and were offered in treatment courses of different lengths. The brand's principal format has been intravaginal therapy. Depending on the product, treatment is delivered as a cream, ovule, or suppository placed in the vagina with a disposable applicator. The different regimens, including one-, three-, and seven-day courses, reflect formulation and dosage differences rather than a simple ranking from weak to strong. Monistat has also offered external products designed to relieve itching and irritation around the vulva. Consumer instructions distinguish these symptom-relief products from the antifungal medicine used to treat the infection. Over time, Monistat became a prominent name in the U.S. women's health and over-the-counter antifungal category. Its retail presence has included drugstores, mass merchants, supermarkets, and online sellers. Marketing and packaging have generally emphasized convenience, recognizable treatment-course choices, and the ability to manage a familiar infection at home. The brand's audience is primarily adult consumers seeking treatment for symptoms they identify as consistent with a previously diagnosed yeast infection. Monistat was part of the Insight Pharmaceuticals portfolio before Insight was acquired by Prestige Consumer Healthcare in 2016. The transaction expanded Prestige's collection of over-the-counter health and personal-care brands and made Monistat part of Prestige's women's health business. Prestige continues to list Monistat among its brands and maintains the brand's U.S. consumer presence. The brand's public-health context is important to its history and positioning. Vaginal itching, discharge, odor, and irritation are not specific to yeast infections, and inappropriate self-treatment can delay diagnosis of another condition. Monistat labeling therefore includes directions and warnings covering first-time symptoms, pregnancy, recurrence, possible exposure to sexually transmitted infections, severe or unusual symptoms, and symptoms that do not resolve. Product information also notes possible local irritation and advises users to follow the instructions for the particular formulation. Monistat remains an active consumer brand rather than a discontinued or independent corporate company.

• 2016

  Prestige acquires Insight Pharmaceuticals

  [3]Prestige Brands announces completion of Insight Pharmaceuticals acquisitionir.prestigebrands.com

  Prestige Consumer Healthcare completed its acquisition of Insight Pharmaceuticals, adding Monistat and other Insight consumer-health brands to its portfolio.

A widely recognized U.S. self-care brand offering nonprescription miconazole treatments for vaginal yeast infections, with multiple treatment durations and formulations.

• Vaginal antifungal

  Monistat 1

  A single-dose miconazole vaginal treatment sold for consumers seeking a one-day regimen for vaginal yeast infection. The product is supplied in a formulation-specific applicator or ovule package, and users are directed to follow the current package instructions rather than assuming that all Monistat 1 versions have identical dosage forms.

• Vaginal antifungal

  Monistat 3

  A three-day miconazole treatment for vaginal yeast infection. Depending on the package version, the medicine is delivered as a vaginal cream or ovule-style product with applicators. It represents the brand's intermediate-duration option and is intended for use according to the labeled schedule.

• Vaginal antifungal

  Monistat 7

  A seven-day miconazole vaginal treatment. The longer regimen is marketed as a conventional course option and is supplied in a formulation designed for repeated intravaginal application. Consumers are instructed to complete the labeled course and to consult a healthcare professional when symptoms are atypical, recurrent, or persistent.

• External symptom relief

  Monistat external anti-itch products

  External-use products intended to temporarily relieve itching and irritation associated with a vaginal yeast infection. These products address external symptoms and do not replace the internal antifungal treatment when treatment of the infection itself is required.

• 2016

  Integration into Prestige's consumer-health portfolioM&A

  Background

  Monistat was part of Insight Pharmaceuticals' portfolio before Prestige Consumer Healthcare agreed to acquire the company.

  Action taken

  Prestige completed the acquisition of Insight Pharmaceuticals and assumed ownership of its brands, including Monistat.

  Aftermath

  Monistat became part of Prestige's women's health and broader over-the-counter brand portfolio.

  Source

1. 1Prestige Consumer Healthcare: Monistat brand pageprestigeconsumerhealthcare.com
2. 2MONISTAT official consumer websitemonistat.com
3. 3Prestige Brands announces completion of Insight Pharmaceuticals acquisitionir.prestigebrands.com